Zurich, Switzerland–(Newsfile Corp. – January 8, 2026) – Lookthrough, the AI-powered platform for real estate investors, today announced the appointment of three new strategic board members with deep expertise in corporate transformation, change management, and asset management: Maria Sourlas of Tata Consulting Services, Domenico Scala, Chairman of Davidoff, and Wijnand Donkers, former CEO of Vonovia. […]

HARBIN, China, Jan. 08, 2026 (GLOBE NEWSWIRE) — According to Xinhuanet, which participated in the event's coverage throughout all stages, the “Global Mayors Dialogue in Harbin” opened on January 6 in northeast China's Heilongjiang Province, gathering mayors and representatives from countries including Canada, Finland and the Republic of Korea (ROK) in Harbin, hailed as China's

Global mayors' dialogue in Harbin charts course for sustainable winter economy GlobeNewswire January 08, 2026 HARBIN, China, Jan. 08, 2026 (GLOBE NEWSWIRE) — According to Xinhuanet, which participated in the event's coverage throughout all stages, the “Global Mayors Dialogue in Harbin” opened on January 6 in northeast China's Heilongjiang Province, gathering mayors and representatives from

Singapore, Jan. 08, 2026 (GLOBE NEWSWIRE) — In a saturated landscape of fragmented AI tools, Wery AI (https://www.weryai.com/) is redefining the creative process with an all-in-one platform that puts powerful, professional-grade video and image generation at users' fingertips. By integrating AI video creation, image editing, character animation, subtitle translation, and more into a seamless workflow,

(TSX-V:RKV),(Boerse Frankfurt – Freiverkehr:7JO0), VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery and Variational AI, a leader in generative artificial intelligence for small-molecule design, today announced the expansion of their collaboration focused on the continued

Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with EBX-102-02 outperforming placebo throughout the study (final assessment at Week 7) Durable improvements observed across abdominal pain, bowel habit parameters and IBS-specific quality of life, with benefit demonstrated in both constipation and diarrhoea-predominant IBS EBX-102-02

(NasdaqGM:OCS),(Iceland:OCS),(Iceland:OCS.IC), Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. alone Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) expected in Q2 2026 Riad Sherif,

STEVENAGE, United Kingdom, Jan. 08, 2026 (GLOBE NEWSWIRE) — NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being

Wery AI Launches All-in-One Creative Suite to Simplify Professional Content Creation GlobeNewswire January 08, 2026 Singapore, Jan. 08, 2026 (GLOBE NEWSWIRE) — In a saturated landscape of fragmented AI tools, Wery AI (https://www.weryai.com/) is redefining the creative process with an all-in-one platform that puts powerful, professional-grade video and image generation at users' fingertips. By integrating

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference GlobeNewswire January 08, 2026 Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. alone Multiple milestones anticipated from late-stage portfolio including topline results